热门资讯> 正文
Ardelyx季度业绩上涨13%
2024-05-03 05:38
- Ardelyx (NASDAQ:ARDX), aided by strong sales of its chronic kidney disease drug Xphozah (tenapanor) in its first full quarter on the market, beat 2024 Q1 expectations on the top and bottom line.
- Xphozah, which won U.S. FDA approval in October 2023, brought in $15.2M in the quarter.
- The company's other marketed treatment, Ibsrela (tenapanor), approved for irritable bowel syndrome with constipation, had revenue of ~$28.4M, compared to ~$11.4M in the year-ago period.
- Ardelyx's (ARDX) net loss narrowed ~1% year over year to ~$26.5M. Net loss per share, basic and diluted, improved to -$0.11 from -$0.13.
- Shares are up ~13% in after-hours trading Thursday.
More on Ardelyx
- Ardelyx Shrugs Off 'Mixed' Q4 Earnings
- Ardelyx, Inc. (ARDX) Q4 2023 Earnings Call Transcript
- Ardelyx Q4 Preview: Recent Bull Run May Pause While Market Digests 2024 Guidance
- Ardelyx spikes as kidney patient bill advances in Congress
- Ardelyx down 8% after hours as Q4 bottom line disappoints
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
